ASR Vermogensbeheer N.V. Invests $378,000 in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• ASR Vermogensbeheer N.V. has invested approximately $378,000 in United Therapeutics Corporation by purchasing 1,227 shares during the first quarter.
• Many institutional investors have also increased their positions in United Therapeutics, with firms like GAMMA Investing LLC boosting their stake by 29,415.2%.
• Analysts have varied opinions on United Therapeutics, with an average price target of $379.69 and several firms lowering their target prices, indicating a cautious outlook despite a majority buy rating.

ASR Vermogensbeheer N.V. purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,227 shares of the biotechnology company's stock, valued at approximately $378,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dunhill Financial LLC raised its stake in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares in the last quarter. Sound Income Strategies LLC acquired a new position in United Therapeutics in the first quarter valued at about $49,000. State of Wyoming acquired a new position in United Therapeutics in the fourth quarter valued at about $62,000. Curat Global LLC acquired a new position in United Therapeutics in the first quarter valued at about $63,000. Finally, Natixis acquired a new position in United Therapeutics in the fourth quarter valued at about $85,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $10,297,208.76. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares of the company's stock, valued at $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,681 shares of company stock valued at $24,618,359 over the last three months. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Down 0.4%

United Therapeutics stock traded down $1.07 during trading hours on Monday, hitting $300.43. The stock had a trading volume of 575,733 shares, compared to its average volume of 619,092. The stock has a market cap of $13.55 billion, a price-to-earnings ratio of 11.73, a P/E/G ratio of 4.57 and a beta of 0.57. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The business's 50 day simple moving average is $296.14 and its 200-day simple moving average is $310.09.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.85 earnings per share. Research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Bank of America dropped their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Cantor Fitzgerald assumed coverage on United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective for the company. Morgan Stanley dropped their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, HC Wainwright set a $400.00 price objective on United Therapeutics and gave the stock a "buy" rating in a research report on Thursday, July 31st. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $379.69.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.